Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Haichuan Hu, Ph.D.

Title
Institution
Department
Address
Profile Picture

Biography
Fudan UniversityMD06/2012Clinical Medicine
Fudan University Shanghai Cancer CenterResident Trainee09/2014Clinical Oncology
2012
Outstanding Graduate Studies
2013
Shanghai Science and Technology Award
2016
Award for Outstanding Research in Respiratory Disease

Overview

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. (Haichuan Hu) Nov 1, 2017 - Oct 31, 2019
    Lung Cancer Research Foundation
    Targeting the tumor microenvironment to enhance NSCLC targeted therapy
    Role Description: The goal of the study is to decipher the heterogeneous impact of the tumor microenvironment on targeted therapy efficacy and to identify resistance-driving cytokine secreted by tumor stromal cells to design novel and effective combination therapies to enhance EGFR TKI response.
    Role: Principle Investigator
  2. (Cyril Benes) Nov 1, 2017 - Oct 31, 2018
    Harvard Catalyst
    Targeting growth factors and cytokine secretion in tumor associated fibroblasts to counter therapeutic resistance in non-small cell lung cancer
    Role: Co-Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Kuang M, Shen X, Yuan C, Hu H, Zhang Y, Pan Y, Cheng C, Zheng D, Cheng L, Zhao Y, Tao X, Li Y, Chen H, Sun Y. Clinical Significance of Complex Glandular Patterns in Lung Adenocarcinoma: Clinicopathologic and Molecular Study in a Large Series of Cases. Am J Clin Pathol. 2018 May 31; 150(1):65-73. PMID: 29746612.
    Citations:    Fields:    
  2. Li B, Hu H, Zhang Y, Zhang J, Miao L, Ma L, Luo X, Zhang Y, Ye T, Li H, Zhou J, Li Y, Shen L, Zhao K, Fan M, Zhu Z, Wang J, Xu J, Deng Y, Lu Q, Jia H, Cheng X, Li H, Zhang Y, Li C, Pan Y, Liu S, Hu H, Shao L, Sun Y, Xiang J, Chen H. Extended Right Thoracic Approach Compared With Limited Left Thoracic Approach for Patients With Middle and Lower Esophageal Squamous Cell Carcinoma: Three-year Survival of a Prospective, Randomized, Open-label Trial. Ann Surg. 2018 May; 267(5):826-832. PMID: 28448385.
    Citations: 3     Fields:    
  3. Song KA, Niederst MJ, Lochmann TL, Hata AN, Kitai H, Ham J, Floros KV, Hicks MA, Hu H, Mulvey HE, Drier Y, Heisey DAR, Hughes MT, Patel NU, Lockerman EL, Garcia A, Gillepsie S, Archibald HL, Gomez-Caraballo M, Nulton TJ, Windle BE, Piotrowska Z, Sahingur SE, Taylor SM, Dozmorov M, Sequist LV, Bernstein B, Ebi H, Engelman JA, Faber AC. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. Clin Cancer Res. 2018 01 01; 24(1):197-208. PMID: 29051323.
    Citations: 1     Fields:    
  4. Pan Y, Zheng D, Li Y, Cai X, Zheng Z, Jin Y, Hu H, Cheng C, Shen L, Wang J, Ji H, Sun Y, Zhou X, Chen H. Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. J Thorac Dis. 2017 Aug; 9(8):2579-2586. PMID: 28932565.
    Citations: 3     
  5. Hu H, Sun Z, Li Y, Zhang Y, Li H, Zhang Y, Pan Y, Shen L, Wang R, Sun Y, Chen H. The Histologic Classifications of Lung Adenocarcinomas Are Discriminable by Unique Lineage Backgrounds. J Thorac Oncol. 2016 12; 11(12):2161-2172. PMID: 27496649.
    Citations: 1     Fields:    Translation:Humans
  6. Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HE, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raoof S, Lockerman E, Kalsy A, Lee D, Keating CL, Ruddy DA, Damon LJ, Crystal AS, Costa C, Piotrowska Z, Bardelli A, Iafrate AJ, Sadreyev RI, Stegmeier F, Getz G, Sequist LV, Faber AC, Engelman JA. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016 Mar; 22(3):262-9. PMID: 26828195.
    Citations: 89     Fields:    Translation:HumansCells
  7. Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clin Cancer Res. 2015 Sep 01; 21(17):3924-33. PMID: 25964297.
    Citations: 81     Fields:    Translation:HumansCells
  8. Hu H, Pan Y, Li Y, Wang L, Wang R, Zhang Y, Li H, Ye T, Zhang Y, Luo X, Shao L, Sun Z, Cai D, Xu J, Lu Q, Deng Y, Shen L, Ji H, Sun Y, Chen H. Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. Onco Targets Ther. 2014; 7:1423-37. PMID: 25152623.
    Citations: 14     
  9. Wang R, Pan Y, Li C, Zhang H, Garfield D, Li Y, Ye T, Hu H, Luo X, Li H, Zhang Y, Zhang J, Zhou X, Shen L, Pao W, Sun Y, Chen H. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. J Thorac Oncol. 2014 Jun; 9(6):760-8. PMID: 24481316.
    Citations: 15     Fields:    Translation:Humans
  10. Wang R, Wang L, Li Y, Hu H, Shen L, Shen X, Pan Y, Ye T, Zhang Y, Luo X, Zhang Y, Pan B, Li B, Li H, Zhang J, Pao W, Ji H, Sun Y, Chen H. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res. 2014 Aug 01; 20(15):4107-14. PMID: 24850843.
    Citations: 34     Fields:    Translation:Humans
  11. Zhang Y, Wang L, Li Y, Pan Y, Wang R, Hu H, Li H, Luo X, Ye T, Sun Y, Chen H. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther. 2014; 7:567-73. PMID: 24748806.
    Citations: 63     
  12. Li H, Hu H, Wang R, Pan Y, Wang L, Li Y, Zhang Y, Ye T, Zhang Y, Li B, Shen L, Sun Y, Chen H. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. Onco Targets Ther. 2014; 7:513-24. PMID: 24729716.
    Citations: 10     
  13. Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, Zhang Y, Wang L, Luo X, Li H, Li Y, Shen L, Sun Y, Chen H. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest. 2014 Mar 01; 145(3):473-479. PMID: 24158231.
    Citations: 9     Fields:    Translation:Humans
  14. Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, Wang R, Ye T, Luo X, Zhang Y, Li B, Cai D, Shen L, Sun Y, Chen H. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer. 2014 May; 84(2):121-6. PMID: 24629636.
    Citations: 61     Fields:    Translation:Humans
  15. Wang L, Hu H, Pan Y, Wang R, Li Y, Shen L, Yu Y, Li H, Cai D, Sun Y, Chen H. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One. 2014; 9(2):e88291. PMID: 24533074.
    Citations: 33     Fields:    Translation:Humans
  16. Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, Wang R, Ye T, Luo X, Zhang Y, Li B, Cai D, Shen L, Sun Y, Chen H. Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma. Ann Surg Oncol. 2014 Dec; 21 Suppl 4:S490-6. PMID: 24419753.
    Citations: 5     Fields:    Translation:HumansCells
  17. Zhang Y, Sun Y, Wang L, Ye T, Pan Y, Hu H, Yu Y, Zhao N, Song Y, Garfield D, Chen H. Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials. Onco Targets Ther. 2013; 6:1771-7. PMID: 24348052.
    Citations: 5     
  18. Li Y, Pan Y, Wang R, Sun Y, Hu H, Shen X, Lu Y, Shen L, Zhu X, Chen H. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One. 2013; 8(7):e69016. PMID: 23922677.
    Citations: 27     Fields:    Translation:Humans
  19. Zhang Y, Sun Y, Li Y, Fang Z, Wang R, Pan Y, Hu H, Luo X, Ye T, Li H, Wang L, Chen H, Ji H. ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma. Ann Surg Oncol. 2013 Dec; 20 Suppl 3:S577-82. PMID: 23775406.
    Citations: 6     Fields:    Translation:Humans
  20. Liu Y, Luo X, Hu H, Wang R, Sun Y, Zeng R, Chen H. Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer. PLoS One. 2012; 7(12):e51748. PMID: 23284758.
    Citations: 23     Fields:    Translation:Humans
  21. Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, Luo X, Wang L, Li H, Zhang Y, Li F, Lu Y, Lu Q, Xu J, Garfield D, Shen L, Ji H, Pao W, Sun Y, Chen H. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol. 2012 Dec 10; 30(35):4352-9. PMID: 23150706.
    Citations: 98     Fields:    Translation:Humans
  22. Li H, Pan Y, Li Y, Li C, Wang R, Hu H, Zhang Y, Ye T, Wang L, Shen L, Sun Y, Chen H. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer. 2013 Jan; 79(1):8-13. PMID: 23098378.
    Citations: 33     Fields:    Translation:Humans
  23. Li B, Chen H, Xiang J, Zhang Y, Li C, Hu H, Zhang Y. Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single-institution experience. J Thorac Cardiovasc Surg. 2012 Oct; 144(4):778-85; discussion 785-6. PMID: 22889480.
    Citations: 12     Fields:    Translation:Humans
  24. Wang R, Pan Y, Li C, Hu H, Zhang Y, Li H, Luo X, Zhang J, Fang Z, Li Y, Shen L, Ji H, Garfield D, Sun Y, Chen H. The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res. 2012 Sep 01; 18(17):4725-32. PMID: 22791881.
    Citations: 20     Fields:    Translation:Humans
  25. Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, Luo X, Ye T, Wang R, Hu H, Li H, Wang L, Pao W, Chen H. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res. 2012 Apr 01; 18(7):1947-53. PMID: 22317764.
    Citations: 62     Fields:    Translation:Humans
  26. Li C, Sun Y, Fang R, Han X, Luo X, Wang R, Pan Y, Hu H, Zhang Y, Pao W, Shen L, Ji H, Chen H. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol. 2012 Jan; 7(1):85-9. PMID: 22071781.
    Citations: 20     Fields:    Translation:Humans
  27. Hu H, Yang J, Sun Y, Yang Y, Qian J, Jin L, Wang M, Bi R, Zhang R, Zhu M, Sun M, Ma H, Wei Q, Jiang G, Zhou X, Chen H. Putatively functional PLCE1 variants and susceptibility to esophageal squamous cell carcinoma (ESCC): a case-control study in eastern Chinese populations. Ann Surg Oncol. 2012 Jul; 19(7):2403-10. PMID: 22203178.
    Citations: 20     Fields:    Translation:Humans
  28. Hu H, Ye T, Tan D, Li H, Chen H. Is anterior mediastinum route a shorter choice for esophageal reconstruction? A comparative anatomic study. Eur J Cardiothorac Surg. 2011 Dec; 40(6):1466-9. PMID: 21550263.
    Citations: 4     Fields:    Translation:Humans
  29. Luo X, Liu Y, Wang R, Hu H, Zeng R, Chen H. A high-quality secretome of A549 cells aided the discovery of C4b-binding protein as a novel serum biomarker for non-small cell lung cancer. J Proteomics. 2011 Apr 01; 74(4):528-38. PMID: 21262398.
    Citations: 11     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Hu's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (136)
Explore
_
Co-Authors (10)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.